about kinex
Kinex is a specialty pharmaceutical company focused on the development and commercialization of next generation therapies for cancer and immunomodulatory diseases.
Our Company >>clinical trials
Kinex plans to enter multiple Phase 2 studies with KX01 in 2013. Clinical studies will include Acute Myeloid Leukemia (AML), and Chronic Myeloid Leukemia (CML).
Clinical Trials >>News/Events
Kinex Pharmaceuticals and Zenith Technology Corporation Announce the Execution of a Collaborative Licensing Agreement
Monday, May 6th, 2013
Kinex Pharmaceuticals and Zenith Technology Corporation, through its affiliate ZenRx, announced today the execution of a collaborative licensing agreement granting Zenith Technology
Kinex Pharmaceuticals’ Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Society’s 2013 Honoree for its Cuisine for a Cure event
Friday, April 12th, 2013
Kinex Pharmaceuticals announced that Dr. David Hangauer, co-founder and Chief Scientific Officer of Kinex, has been named the American Cancer Society’s 2013


